WallStreetZenWallStreetZen

NASDAQ: AMRS
Amyris Inc Stock

$1.60+0.04 (+2.56%)
Updated Jan 27, 2023
AMRS Price
$1.60
Fair Value Price
$1.62
Market Cap
$520.30M
52 Week Low
$1.25
52 Week High
$5.31
P/E
-1.54x
P/B
-1.22x
P/S
3.64x
PEG
N/A
Dividend Yield
N/A
Revenue
$258.82M
Earnings
-$340.87M
Gross Margin
10.2%
Operating Margin
-124.76%
Profit Margin
-131.8%
Debt to Equity
-2.71
Operating Cash Flow
-$575M
Beta
1.73
Next Earnings
Feb 27, 2023
Ex-Dividend
N/A
Next Dividend
N/A

AMRS Overview

Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.

Zen Score

Industry Average (38)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AMRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AMRS ($1.60) is undervalued by 1.07% relative to our estimate of its Fair Value price of $1.62 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AMRS ($1.60) is not significantly undervalued (1.07%) relative to our estimate of its Fair Value price of $1.62 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AMRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AMRS due diligence checks available for Premium users.

Be the first to know about important AMRS news, forecast changes, insider trades & much more!

AMRS News

Valuation

AMRS fair value

Fair Value of AMRS stock based on Discounted Cash Flow (DCF)
Price
$1.60
Fair Value
$1.62
Undervalued by
1.07%
AMRS ($1.60) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AMRS ($1.60) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AMRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

AMRS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-1.54x
Industry
27.2x
Market
23.59x

AMRS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-1.22x
Industry
3.81x

AMRS's financial health

Profit margin

Revenue
$71.1M
Net Income
-$161.4M
Profit Margin
-226.9%
AMRS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
AMRS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$754.1M
Liabilities
$1.2B
Debt to equity
-2.71
AMRS's short-term liabilities ($309.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AMRS's long-term liabilities ($849.60M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AMRS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AMRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$133.5M
Investing
-$30.1M
Financing
$81.3M
AMRS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AMRS vs Specialty Chemical Stocks

TickerMarket Cap1d %P/EP/B
AMRS$520.30M+2.56%-1.54x-1.22x
GEVO$510.03M+2.38%-5.12x0.82x
FEAM$470.49M-1.11%-10.61x6.84x
HDSN$440.84M-0.41%4.18x2.58x
TG$397.47M-0.60%7.35x1.92x

Amyris Stock FAQ

What is Amyris's quote symbol?

NASDAQ: AMRS) Amyris trades on the NASDAQ under the ticker symbol AMRS. Amyris stock quotes can also be displayed as NASDAQ: AMRS.

If you're new to stock investing, here's how to buy Amyris stock.

What is the 52 week high and low for Amyris (NASDAQ: AMRS)?

(NASDAQ: AMRS) Amyris's 52-week high was $5.31, and its 52-week low was $1.25. It is currently -69.84% from its 52-week high and 28% from its 52-week low.

How much is Amyris stock worth today?

(NASDAQ: AMRS) Amyris currently has 325,188,403 outstanding shares. With Amyris stock trading at $1.60 per share, the total value of Amyris stock (market capitalization) is $520.30M.

Amyris stock was originally listed at a price of $247.50 in Sep 28, 2010. If you had invested in Amyris stock at $247.50, your return over the last 12 years would have been -99.35%, for an annualized return of -34.3% (not including any dividends or dividend reinvestments).

How much is Amyris's stock price per share?

(NASDAQ: AMRS) Amyris stock price per share is $1.60 today (as of Jan 27, 2023).

What is Amyris's Market Cap?

(NASDAQ: AMRS) Amyris's market cap is $520.30M, as of Jan 29, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Amyris's market cap is calculated by multiplying AMRS's current stock price of $1.60 by AMRS's total outstanding shares of 325,188,403.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.